Kumquat Biosciences Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
45
- Latest Deal Type
-
Series A2
- Latest Deal Amount
-
$30M
- Investors
-
8
Kumquat Biosciences General Information
Description
Developer of small molecule oncology therapeutics designed to address cancer treatment resistance. The company's platform develops KRAS-targeted therapies, combination treatment candidates, immune modulation approaches, and clinical-stage oncology programs, enabling biotechnology companies, researchers, and healthcare providers to improve outcomes for patients with difficult-to-treat cancers.
Contact Information
Website
www.kumquatbiosciences.comCorporate Office
- 10770 Wateridge Circle
- Suite 120
- San Diego, CA 92121
- United States
Corporate Office
- 10770 Wateridge Circle
- Suite 120
- San Diego, CA 92121
- United States
Kumquat Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series A2) | 16-Aug-2021 | $30M | Completed | Pre-Clinical Trials | ||
| 2. Early Stage VC (Series A1) | 16-Feb-2021 | Completed | Pre-Clinical Trials | |||
| 1. Early Stage VC (Series A) | 08-Sep-2019 | $55.9M | $55.9M | Completed | Startup |
Kumquat Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-2 | ||||||||
| Series A-1 | ||||||||
| Series A | 20,489,018 | $0.001000 | $2.73 | $2.73 | 1x | $2.73 | 44.07% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Kumquat Biosciences Patents
Kumquat Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026236375-A1 | Bifunctional compounds useful as ras protein degraders | Pending | 07-May-2025 | ||
| WO-2026236340-A1 | Methods of modulating cell proliferation | Pending | 07-May-2025 | ||
| WO-2026193007-A1 | Heterocyclic compounds and uses thereof | Pending | 10-Mar-2025 | ||
| WO-2026193011-A1 | Heterocyclic compounds and uses thereof | Pending | 10-Mar-2025 | ||
| WO-2026112350-A1 | Heterocyclic compounds and uses thereof | Pending | 22-Nov-2024 | A61K40/31 |
Kumquat Biosciences Signals
Kumquat Biosciences Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Sequoia Capital | Venture Capital | Minority | ||
| Boxer Capital | Corporate Venture Capital | Minority | ||
| Codon Capital | Venture Capital | Minority | ||
| EcoR1 Capital | Venture Capital | Minority | ||
| HSG (Hong Kong) | Venture Capital | Minority |
Kumquat Biosciences FAQs
-
When was Kumquat Biosciences founded?
Kumquat Biosciences was founded in 2019.
-
Where is Kumquat Biosciences headquartered?
Kumquat Biosciences is headquartered in San Diego, CA.
-
What is the size of Kumquat Biosciences?
Kumquat Biosciences has 45 total employees.
-
What industry is Kumquat Biosciences in?
Kumquat Biosciences’s primary industry is Drug Discovery.
-
Is Kumquat Biosciences a private or public company?
Kumquat Biosciences is a Private company.
-
What is the current valuation of Kumquat Biosciences?
The current valuation of Kumquat Biosciences is .
-
What is Kumquat Biosciences’s current revenue?
The current revenue for Kumquat Biosciences is .
-
How much funding has Kumquat Biosciences raised over time?
Kumquat Biosciences has raised $136M.
-
Who are Kumquat Biosciences’s investors?
Sequoia Capital, Boxer Capital, Codon Capital, EcoR1 Capital, and HSG (Hong Kong) are 5 of 8 investors who have invested in Kumquat Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process